“夫妻免疫疗法”：CXCL13是处方的核心吗？
"Couple's Immunotherapy": Is CXCL13 at the Heart of the Prescription?
发表日期：2024 Jul 05
作者：
Eduardo Cruz-Hinojoza, Ingunn M Stromnes
来源：
Cancer Immunology Research
摘要：
已经观察到癌症存活率和对免疫治疗的反应存在性别差异，与女性相比，男性通常在免疫检查点封锁方面表现出更好的结果。在本文中，通过询问公共肺癌测序数据集，布伦南和同事发现了一个趋化因子轴，该轴可能导致性别之间不同的免疫治疗结果。参见 Brennan 等人的相关文章，第 17 页。 XXX (3).©2024 美国癌症研究协会。
Sex differences in cancer survivorship and response to immunotherapy have been observed, with males generally displaying better outcomes to immune checkpoint blockade compared with females. In this article, by interrogating public lung cancer sequencing datasets, Brennan and colleagues uncover a chemokine axis that may contribute to disparate immunotherapy outcomes between the sexes. See related article by Brennan et al., p. XXX (3).©2024 American Association for Cancer Research.